Horiba Medical - UK has launched MLT-Diode Laser Systems, specifically designed for veterinary use, as part of its portfolio of animal healthcare products.
According to the company, the MLT-Diode Lasers are highly versatile and can be used in a variety of veterinary applications including surgery, endoscopy, dentistry and irradiation.
The two models, the MLT-Diode Laser Classic and Premium, both feature touch screen controls and are adaptable to each users individual preferences. Designed with small animal practices in mind, the Classic has a performance out-put of 8 watts whilst the more powerful Premium model is for equine medicine with an output of 15 watts. The system is mounted on a mobile cart with a protection case, allowing the whole system to be moved between treatment rooms and enabling near patient application.
Horiba Medical will be exhibiting the MLT-Diode Laser Systems at the London Vet Show at Olympia, 22nd to 23rd October 2010, on Stand M4.
It is hoped the findings, which were unveiled at the House of Commons yesterday, will enable the welfare priorities of the UK’s 800,000 horses to be addressed.
This is the first time welfare organisations, breeders, the equine industry and the veterinary profession have come together to agree on a strategy to best improve the welfare of horses in the UK.
The equine welfare study found the welfare needs of many horses are not currently being met and the report has highlighted four welfare priorities.
Dr Siobhan Mullan, Research Fellow in Animal Welfare Science, Ethics and Law at the University of Bristol and one of the report’s authors, said: "Bringing together the views of people associated with horses in England and Wales has provided an overview of horse welfare, from the day-to-day concerns of equine caregivers to identifying four priority challenges to equine welfare.
"This research has also identified how equine welfare can be improved, by addressing both the priority challenges, and a wider set of industry and horse-based needs."
Roly Owers, World Horse Welfare Chief Executive, added: "This research report provides a vital insight to the UK’s equine sector, mapping out the welfare landscape from a wide range of sector experts and stakeholders.
"In order for World Horse Welfare and others to most effectively address the welfare challenges facing UK equines, we need to better understand today’s welfare priorities and this research will provide a valuable guide to help in driving the focus of our educational initiatives and resources over the next few years.”
The priority welfare challenges and solutions outlined in the report are:
Unresolved stress/pain behaviourProblems associated with unresolved stress/pain behaviour affect large numbers of horses, often for long durations with variable severity of suffering caused to individual horses.
More academic research is needed to fully understand the links between behaviour, stress and pain, and objective measures of stress and pain in horses should be developed. Vets, riding instructors, the Pony Club, riding clubs and the equine press have a role in educating horse caregivers about signs of stress and pain and the appropriate responses. Academics and experts also have a role in tackling this issue through evaluating the effectiveness of intervention programmes.
Inappropriate nutritionOverfeeding and obesity are the main welfare problems associated with nutrition and affect large numbers of horses, often for a long time with varying severity of suffering.
Vets have a key role in tackling the problems associated with inappropriate nutrition. A consistent approach by all vets is needed, to prevent horse owners choosing vets that don’t challenge owners about their horses’ nutrition. Feed companies can also play an important role in tackling this issue, although many feed companies already offer appropriate nutrition for a range of horses and exercise situations. Better owner education, based on existing good research, would ensure the right nutritional choices are made for individual horses.
Inappropriate stabling /turnoutWelfare of horses is compromised when the amount of time spent at pasture/stabled does not meet their individual needs, when they are kept in social isolation or when they are exposed to unsuitable grazing conditions. Welfare problems associated with incorrect stabling/turnout affect large numbers of horses for a long time with variable levels of suffering.
Although all horse owners make choices relating to the amount and type of stabling and turnout experienced by their horses, livery yard owners could play a role in addressing this issue. For example, by encouraging different approaches to management, including group housing and the use of all-weather turnout facilities. Strengthening legislation is another possible way for improvement but a ‘one size fits all’ approach would be inappropriate. For example, for some horses, turn out to pasture may not always be suitable.
Delayed deathHorses may be kept alive inappropriately resulting in firstly, prolonging welfare problems, such as continued suffering of a horse in pain. This affects relatively large numbers of horses, for short periods of time with the severity of suffering often being severe. Secondly, an increased risk of suffering, for example where horses are unwanted by their owners, become low value and subsequently aren’t cared for well.
One way for improvement could be by putting pressure on the EU to make changes to the passport regulations. In particular, legislation changes that would enable horses who had received medications, including Phenylbutazone, to be slaughtered to enter the human food chain after a six month withdrawal period. In addition, challenging negative attitudes of horse owners towards timely euthanasia is important.
The research, undertaken over a four year period, was to understand the welfare status of horses in England and Wales, identify priority welfare issues and explore horse owner and industry experts’ perceptions of these issues.
Stakeholders from across the equine industry contributed to the research: from vets to farriers and welfare charities to governing body representatives, participants represented a wide-reaching cross section of horse care roles and responsibilities.
The hands-on course, which is worth 7 CPD hours, has been organised by Dr Nicola M Parry, Recognised Specialist in Pathology at the University of Surrey School of Veterinary Medicine. It will combine lectures, practicals, and a Q&A session to enable delegates to carry out a post-mortem, identify common (and not so common) pathologies, and draw conclusions about the cause of death.
The morning lectures will provide an overview of techniques that focus on how to approach the post-mortem examination of the adult horse and the foetus/foal, as well as how to examine the placenta. Potential findings will be discussed as well as some pitfalls to avoid during the post-mortem examination, and how to optimise sample submission. The lectures will be recorded, enabling sessions to be reviewed later.
Delegates will spend the afternoon in the post-mortem room, examining macroscopic specimens and learning practical approaches to a post-mortem examination in the field, and the collection of key specimens. The day will close with a Q&A session.
Speakers Dr Fabio Del Piero from the Louisiana State University and Dr Marvin J Firth from the University of Surrey will help delegates to:
Sarah Gaspar, the Learning Manager at BEVA said: “If you have ever been called out to a dead horse to find a distraught owner and not been sure how to identify the cause, this course is for you. We can’t remember any course ever having been run on this topic in the UK before; it is likely to be very popular so be quick to book.”
To find out more and to book click here: https://www.beva.org.uk/Education/CPD/Event-Details/eventDateId/1582
Merial has launched Equioxx, a new pain management product which the company says is the first COX-2 specific NSAID for horses
Traditional NSAIDs act by blocking the action of both COX-1 and COX-2 enzymes at the same time. Although COX-2 produces prostaglandins associated with both inflammation and pain, COX-1 has a pivotal role in maintaining normal physiological function, so inhibiting this enzyme may have an increased risk of side effects e.g. gastric ulceration. Merial says Equioxx is the only NSAID that is highly COX-2 selective (up to 643 times more selective for COX-2 than COX-1), acting to reduce pain and inflammation but without affecting the COX-1 enzyme at therapeutic levels.
Equioxx contains the active ingredient firocoxib, and Merial says it is proven to be effective at reducing chronic lameness in horses. Appearing in blood plasma within 30 minutes of oral dosing, its pharmacokinetic profile allows once daily dosing. Field studies have confirmed that firocoxib is highly effective at controlling pain and improving function in horses with chronic osteoarthritis.
Equioxx is available as either a low dose injectable solution or a palatable oral paste.
For more information contact Merial Customer Services on 0870 6000 123
Janssen Animal Health has launched a range of skincare products - Cavalesse® and Cavalesse® Topical - to help maintain and support a healthy skin in horses prone to summer skin allergies.
According to the company, summer skin allergies, including sweet itch, which is caused by reactions to bites from Culicoides midges, can be serious and frustrating conditions that affect three to five per cent of all horses in the UK. These allergies can be difficult to manage and are often a real challenge for both horse owners and vets alike.
Cavalesse is a natural food supplement containing a specialised formulation of water-soluble vitamins and minerals, including Nicotinamide. Once a month the contents of each sachet are dissolved in water to form an oral solution, which can be administered daily via a special pipette, either by sprinkling over a small handful of feed or adding to a treat such as a sugar lump. The supplement helps horses maintain a healthy skin by reducing histamine release within the skin, moderating the excessive immune response within the skin, reducing anti-inflammatory reactions and suppressing antigen induced transformation.
To complete the Cavalesse skin management range, Cavalesse Topical is a skincare gel that can be used in combination with the Cavalesse solution. The gel can be applied to the skin to help support natural immunity from the outside, whilst the oral solution works in partnership from the inside.
Helen Goldberg, marketing manager at Janssen Animal Health said: "Summer skin allergies, such as sweet itch, are frustrating conditions that can be difficult to treat. To help prevent the disease, horses are often fully blanketed while out at grass, given limited access to pasture or covered with insect repellents, while treatment has included antihistamines and corticosteroids which can have side-effects.
"Only available via veterinary wholesalers, the Cavalesse range of products will enable owners to protect their horses from the inside, whilst maintaining a healthy skin from the outside."
2ml of Cavalesse should be administered to horses and ponies weighing less than 500kg daily, while horses weighing more than 500kg should be given 3ml per day. Cavalesse Topical should be applied to the skin according to requirements.
For further information, please contact your Janssen Animal Health account manager or phone 01494 567555.
The article argues that as the equine influenza (EI) vaccine supply returns to normal, there is sound scientific evidence why bi-annual vaccination schedules should be re-implemented promptly.
Whilst the scale and number of outbreaks has been relatively small since the introduction of mandatory EI vaccination by most competitive equestrian disciplines in the 1980s, disease events such as those experienced in the UK in 1989, 2003 and most recently in 2019 have demonstrated EI’s epidemic potential, even in vaccinated horse populations.
In their article 'Equine influenza bi-annual boosters: what does the evidence tell us?' Victoria Colgate and Richard Newton discuss what has been learnt from previous outbreaks and explain the evidence from mathematical models to show why bi-annual boosters are beneficial.
The authors say that epidemiological data from previous natural EI outbreaks have repeatedly demonstrated the impermanent nature of the protection provided by vaccination and observational field studies have repeatedly highlighted the potential for 12-monthly boosters to leave a vulnerable immunity gap at both the individual animal and population level.
Mathematical models of EI transmission confirm that six-monthly rather than annual EI booster vaccinations are preferable to establish and maintain effective population level immunity to EI.
Ideally vaccine strains should be updated in a timely manner to ensure inclusion of the most epidemiologically-relevant strains, however, this is a slow and expensive process for equine vaccine manufacturers.
In the absence of updated vaccine strains, bi-annual vaccination is strongly recommended to help compensate for antigenic drift between vaccine and circulating EI viral strains
Professor Celia Marr, Editor of the EVJ said: “Although the recent EI vaccine shortage has necessitated a temporary relaxation of competition vaccine schedules, we must now renew the message that six-monthly boosters are optimal and necessary.”
The Editorial can be found at https://beva.onlinelibrary.wiley.com/doi/10.1111/evj.13898 and is free to view.
Two related articles can be found here: https://beva.onlinelibrary.wiley.com/doi/10.1111/evj.13874 and here: https://beva.onlinelibrary.wiley.com/doi/10.1111/evj.13885
The new pass offers both physical and virtual tickets so that the practice rota doesn't have to stop any member of the team from attending.
BEVA says the new tickets also offer a saving of up to £113 per vet.
David Mountford, Chief Executive of BEVA said: “We know that not every vet at a practice can attend congress every year because someone is always going to have to stay behind and work.
"So, by offering a mix of physical and virtual tickets in the pass it means those staying at home to look after the practice can still benefit from the live stream as well as the six-month access to all the lectures afterwards.
"Congress always contains plenty of relevant and dedicated content for nurses, so the pass obviously includes nurse tickets too.”
Practice Passes are available for BEVA members in three packages: small (£599), medium (£1,333) and large (£2,666).
Individual early bird BEVA member prices are £499 for vets and £187 for vet nurses for all three days (with concessions available for those in their first three years’ post-graduation or on a lower salary).
Practice Passes and early bird tickets are available to purchase until Monday 1 August 2022.
Day tickets are also available.
Virtual tickets are £199 for vets and £40 for nurses.
For more information, or to book tickets, visit http://www.bevacongress.org
I'm delighted to welcome Celia Marr from Rossdales and Edd Knowles from Bell Equine, who have kindly agreed to be our contributing experts. They'll drop in from time to time to add anything helpful they can to the forum discussions.
As elsewhere on VetSurgeon.org, reading content in the new groups or participating in discussions can count towards a VetSurgeon.org CPD certificate. Just press 'Claim CPD' at the top of the page, then collect the record and certificate from your profile.
All members of the site with an interest in equine medicine are now invited to press the join button on the left hand side of the group home page (when viewed on tablet or bigger). You may also wish to select the option to receive a daily or weekly digest of new content by email, which you can cancel at any time.
Equine is the third special interest group launched on VetSurgeon.org. The other two are Small Animal Medicine and Small Animal Dentistry.
BCF has announced the launch of the wireless Cuattro Slate 4 equine DR system.
BCF says the new system is available with an Automatic Exposure Detection (AED) panel, which means the plate automatically recognises the radiation from the generator, with no need for a sync cable.
Gavin Mitchell from BCF said: "This system now makes the connection from any generator to the plate and from plate to tablet now wireless. This is the new revolution for equine DR. Our rugged tablet design makes it easy to show your client your images. All you need to carry with you is the plate, tablet and generator. So much lighter to transport than previous DR systems and now also easier to move around the horse."
Sarah O'Grady from BCF added: "The powerful Cuattro software is so intuitive to use, allowing you to easily customise how your image looks. A simple three step process to take an image and just one button press to back-up images to PACS or the Cloud, makes the Slate so easy to use. If you are considering upgrading to DR or replacing your old DR system, then make sure you try out the new Slate 4."
For more information, visit www.bcftechnology.com or ask your local Account Manager for a free trial.
To nominate someone for inclusion in the showcase, visit: https://www.beva.org.uk/60-Faces
BEVA President Lucy Grieve said: "We are proud of BEVA’s heritage and want to recognise our 60th birthday by celebrating some of those who have made a significant difference to the equine veterinary community. We want you to help us identify the 60 individuals who you believe have truly inspired, influenced and progressed the equine veterinary profession for the better.”
Each of the nominated 60 faces will be highlighted on the website and on BEVA’s social media channels. Profile details will include career paths, workplaces and personal contributions to the equine veterinary profession.
Lucy added: "We have already started the list with Colonel John Hickman, Sue Dyson and Peter Rossdale. But there are hundreds of exceptional, deserving individuals who have made a huge difference to the equine veterinary profession and are worthy of our 60 Faces roll call."
The deadline for nominations is Friday 16th April 2021. All nominations are anonymous.
Dechra Pharmaceuticals PLC has announced that it has acquired the entire issued share capital of Genitrix Limited ("Genitrix") from its owner managers for an initial cash consideration of £5.4 million, with a further £0.8 million being payable upon achievement of specific milestones.
Dechra says the acquisition of Genitrix is consistent with its strategy to grow its international veterinary pharmaceutical business. In the year ended 31 March 2010, Genitrix achieved revenues of £2.4 million.
Ian Page, Chief Executive of Dechra, said: "Genitrix range of equine and companion animal products enhances and complements our UK product portfolio. Furthermore the recently approved canine epilepsy product, Libromide, provides future growth opportunities through potential mutual recognition in Europe. The acquisition is expected to be earnings enhancing in the first full year following ownership."
The Association is also encouraging horse owners to join in the celebrations by sharing birthday cakes with their vet or veterinary practice.
BEVA President Huw Griffiths said: "Our 60 faces initiative celebrates some of the many outstanding people who have left an indelible mark on the profession and whose actions complement BEVA’s work in championing progress and/or diversity."
The list of 60 faces, which were nominated by BEVA members, showcases people who have inspired, influenced and progressed the equine veterinary profession for the better.
The faces range from 16th Century humanist Thomas Blundeville to 21st Century social media entrepreneur Ebony Escalona.
Every day for a month, two faces will be released on BEVA’s social media channels.
Huw added: “It was a really tough challenge to whittle the list down to 60 people as all of the nominees were exceptional individuals.
“The list showcases some of the best-known names in the industry as well as some heroes whose stories are less well known or who have been consigned to history.
“It’s not a “Top 60”, nor are all the faces vets, but it does highlight the breadth of people who have impacted what we do.
"We hope you will enjoy reading about them and we hope our lovely clients will join in the celebrations during the week starting 18th November by sharing a celebratory piece of birthday cake with their cherished horse vet!”
You can see the 60 Faces here: https://www.beva.org.uk/60-Faces
Vets with Horsepower is organised annually by Professor Derek Knottenbelt to help raise funds for equine and human charities around the world.
This year the group undertook an endurance motorbike trip of over 1600 miles: from the UK to Germany, across Scandinavia and back, hosting education events for equine vets along the way to raise funds for four charities including BEVA's Power for Ukraine.
BEVA Council member Alison Talbot, said: “Thanks to the generosity of equine vets in the UK we had just hit the halfway mark of raising £10,000, before Vets with Horsepower set off on their epic Scandinavian mission.
"We are so grateful for their donation of £9922 which means we can now buy another five generators, to help twice as many vets and horses in extremely difficult circumstances during enforced power cuts."
The generators will be transported to a collection point in Poland and then on to Ukraine in time for winter.
Donations to the BEVA Trust Power To Ukraine appeal can be made here: https://www.justgiving.com/campaign/powertoukraine
Any surplus funds will be added to the general fund to support equids in Ukraine.
A new study1 published in the Equine Veterinary Journal's (EVJ) special American Association of Equine Practitioners supplement has concluded that maggots can play an integral role in modern veterinary care for a variety of wounds in horses.
The study assessed the efficacy of maggot debridement therapy in a diversity of equine lesions and found that the method was beneficial in 93% of cases.
Maggots have been used for the treatment of wounds for hundreds of years. Freshly emerged, germ-free larvae of the common green bottle fly are usually used for the purpose. Their wound-healing action is attributed to a debridement effect, an antiseptic effect, a direct effect on cytokine and cell proliferation involved in wound healing and breakdown of biofilm formation. Maggots also destroy and digest bacteria and may also be beneficial in the fight against multi-drug-resistant bacteria such as MRSA.
The study involved the retrospective analysis of 41 horses with various lesions including foot injury, limb laceration, soft tissue abscesses and musculoskeletal infection. Depending on the type, size and location of the wound the maggots were applied either in direct or indirect contact. In some cases a second maggot application was necessary to reach the desired level of healing. Debridement, disinfection and healing occurred in all but three cases, in less than a week. Of the three that did not respond two were complicated by the presence of tumours and one by pre-existing damage to the underlying bone.
Olivier Lepage of the University of Lyon, who led the study, said: "These results show that maggot debridement therapy potentially has an integral place in modern veterinary wound care. It can be used to treat many types of lesions, although not those involving tumours or bone sequestration. Associated high costs present a limiting factor but maggot debridement therapy should certainly be considered for lesions that fail to respond to conventional methods."
Professor Celia Marr, Editor of the EVJ, said: "Horses often suffer from non-healing wounds, particularly in the limbs where the skin is under continuous movement and there is very little subcutaneous tissue. Although at first glance this study might seem counter-intuitive and we might think of maggots as being the last thing one would want on a clean wound, it shows that maggots can be an effective way to clear damaged tissue and this is an important adjunctive approach in equine wound management."
1The use of maggot debridement therapy in 41 equids OM Lepage, A Doumbia, MF Perron-Lepage and M Gangl. EVJ ISSN 0425-1644 DOI: 10.1111/j.2042-3306.2012.00609.x
The study is published by Wiley-Blackwell and can be accessed at http://onlinelibrary.wiley.com/doi/10.1111/j.2042-3306.2012.00609.x/abstract
Strangvac has been in development for over 25 years and Dechra says it's the first and only intramuscular vaccine to help protect against strangles.
Strangvac contains recombinant proteins CCE, Eq85 and IdeE from Streptococcus equi and has DIVA (Differentiating Infected from Vaccinated Animals) capability.
The vaccine contains no live bacteria or bacterial DNA, so will not trigger positive culture or PCR tests.
In trials the new vaccine protected more than 94% of horses1.
Dechra says it reduces the clinical signs of strangles including a high temperature, coughing, inappetence, difficulty swallowing and changes in demeanour, while also reducing the number of lymph node abscesses.
Strangvac can be given to foals from five months of age and two injections should be given at a four-week interval.
Horses at high risk of Streptococcus equi infection, such as those in livery, should be revaccinated after two months.
Based on measured antibody titres, immunological memory was found in horses following repeated vaccination six months after primary vaccination.
Dr Andrew Waller, chief scientific officer at Intervacc AB, the company that developed the vaccine, said: “Strangvac is a ground-breaking new vaccine which, alongside good stable management and biosecurity procedures, can play a really important role in improving herd immunity and reducing the number of strangles cases in the equine population, thereby preventing major economic loss to the equestrian industry.”
https://www.dechra.co.uk/equine/vaccines
Boehringer Ingelheim Vetmedica, manufacturer of the equine pergolide Prascend, has joined forces with the British Horse Society, Redwings Horse Sanctuary and World Horse Welfare to launch the 'Talk About Cushing's (TAC)' campaign.
The initiative, which will take place throughout September and October 2011, is aimed at raising awareness of Cushing's Disease and its clinical signs, perhaps the most familiar of which is hirsutism (abnormal hair growth, or delayed shedding). Horse owners can download a £15 money-off voucher from http://www.talkaboutcushings.co.uk/ throughout the TAC initiative, which can be redeemed through their veterinary practice against blood test costs.
Boehringer says Equine Cushing's Disease, also known as Pituitary Pars Intermedia Dysfunction (PPID), is the most common endocrine disorder in older horses and ponies1 ,and that some estimates suggest over 15% of horses and ponies over 15 years of age are affected2.
Unfortunately, the initial stages of Cushing's Disease are often difficult to detect, delaying the maximum benefit of early diagnosis and intervention. Blood testing is increasingly used to detect the disease and confirm diagnosis, however many horses with clinical signs, including recurrent laminitis, still go undiagnosed.
Craig Beck, vet and equine sales and marketing manager at Boehringer Ingelheim Vetmedica said: "More than 80% of horses suffering from laminitis may have an underlying endocrine disorder, such as Cushing's Disease3.
"The TAC campaign will raise awareness of Cushing's Disease amongst both veterinary professionals and owners. It should make it easier for vets to go ahead with endocrine testing in horses and ponies with recurrent laminitis, diagnosing and treating earlier in the course of the disease."
Lee Hackett, head of welfare at the BHS, added: "Cushing's Disease is relatively common in horses yet in our experience it frequently goes undiagnosed and untreated. This is why we are fully behind the 'Talk About Cushing's' campaign - anything that raises awareness and understanding of this disease has to be of benefit to equine welfare."
Redwings' head of veterinary services Nicky Jarvis said: "At Redwings we have many horses over the age of 15, all living very happy and healthy lives. 'Old age' is not in itself a disease so when a geriatric horse loses condition or appears unwell there is always an underlying cause. If a horse continually succumbs to laminitis or loses weight, Cushing's Disease could be one explanation. However, with early diagnosis, good management and the correct treatment a horse with Cushing's can live comfortably for many years."
"Early diagnosis of Cushing's Disease can be of great benefit, other conditions such as laminitis are often associated with it and it is important that clinical signs are recognised and treated appropriately. World Horse Welfare supports the 'Talk About Cushing's' campaign as it will help people to recognise the signs and take the right action to prevent horses from suffering," concludes Tony Tyler, deputy chief executive, World Horse Welfare.
Backed by an advertising and PR campaign in the equine consumer media, Boehringer Ingelheim Vetmedica has produced a marketing pack for veterinary practices to use in the run up to, and during TAC. This includes leaflets, invoice stickers, a veterinary practice toolkit featuring an owner evening presentation, editorial copy for newsletters and websites and images to support the campaign.
For further information on TAC or Prascend, the first licensed product for the treatment of Cushing's Disease, please visit http://www.talkaboutcushings.co.uk/, contact your Boehringer Ingelheim Vetmedica territory manager or call 01344 746959.
References
1. Donaldson et al. “Evaluation of suspected pituitary pars intermedia dysfunction in horses with laminitis”. JAVMA, Vol 224, No. 7, April 1, 20042. McGowan. “Diagnostic and Management Protocols for Equine Cushings Syndrome” In Practice, November/December 20033. McGowan. “Epidemiology and Clinical Perspectives of Endocrinopathic Laminitis”, BEVA Congress 2009
Every UK-based veterinary surgeon that registers as a member of www.vetsurgeon.org by 1st November 2010 will be entered into a draw to win an Apple iPad 32GB Wi-Fi worth £500.
All existing veterinary surgeon members will also be entered into the draw automatically, so there's no need to re-register. Still, you might like to spread the word about the draw amongst colleagues.
Full terms and conditions are available by clicking here.
Merial has launched a limited trial pack version of Equioxx® (firocoxib), the company's COX-2 specific NSAID for horses, which contains 10 tubes of the oral paste.
According to the company, Equioxx is the only equine NSAID that is highly COX-2 selective, acting to reduce pain and inflammation whilst preserving the natural physiological effects of the COX-1 enzyme, at therapeutic levels.
The company also claims that field studies have confirmed that firocoxib is highly effective at controlling pain and improving function in horses with chronic osteoarthritis.
Jim Tipp BVSc MRCVS, partner at Shropshire based Fyrnwy Equine Clinics said: "As a COX-2 specific NSAID it is not only a good analgesic, but is also an excellent anti-inflammatory. In addition, the COX-1 sparing properties of Equioxx are beneficial where there is increased risk of ulceration."
Equioxx is also available as a low dose injectable solution. For more information contact Merial Customer Services on 0870 6000 123.
The new Tosoh AIA 900 analysers have been trialled for the last 18 months at Liphook Equine Hospital, which was the first practice to introduce ACTH testing for horses 25 years ago and gets hundreds of blood samples every week from veterinary practices all over the UK and Europe.
Professor Andy Durham, who heads up the laboratory at Liphook, said the test period has shown that the new machine produces more accurate results primarily because it’s less sensitive to ACTH degrading in blood samples between collection and receipt by the laboratory.
Andy said: “There are several analytic methods available for use in horses, and we wanted to see if this alternative machine had diagnostic benefits over the ones we’d used previously.
"The ACTH molecule we test for immediately begins to break down after a blood sample is taken, even if you handle it carefully and place it in chilled packaging, but this new analyser is able to detect much more of the degraded ACTH molecule, and therefore it gives a more accurate result.
“As a comparison, ACTH values measured using the previous method suffered about three to four times more degradation over 24 hours.
"What this means for horse owners is that it will reduce the risk of false negative results in ACTH tests, so more horses suffering from Cushing’s disease will receive the treatment they need.”
In testing, the new analysers also demonstrated greater accuracy when measuring insulin levels in blood samples.
https://liphookequinehospital.co.ukhttps://www.rainbowequinehospital.co.uk https://www.rossdales.com
Fort Dodge (makers of Equest equine worming brands, and Deosect), is launching a new Equine Parasites Reference Manual.
The manual, which is supported by AHDA, AMTRA and BEVA, is billed as 'an objective and comprehensive reference guide covering endoparasites and ectoparasites and their control, as well as offering prescribing tips, a glossary of terms and reference sources'.
Fort Dodge has produced the manual to provide an ‘all in one’ guide to support veterinary professionals and Suitably Qualified People (SQPs) involved in prescribing equine parasite treatments. It brings together, in an A5 spiral bound booklet, all the information they may need on the full range of licensed veterinary medicines to control equine parasites of concern in the UK. It will be launched at BETA (17-19 February at the NEC).
For further information about the manual (or to get a copy), please contact Fort Dodge on 01489 781711.
They say that they've been aware of minor interruptions to the supply of such vaccines throughout 2022.
However, a significant, pan-European logistical problem being experienced by Boehringer Ingelheim has raised the prospect of a further reduction in supplies in the coming months.
BEVA is liaising with the three vaccine manufacturers to quantify the impact of the shortage and to consider solutions, both to minimise the threat to equine health and to prevent disruption to equestrian competition.
Marc Laemmer, equine business head at Boehringer Ingelheim Animal Health, said: “We are currently experiencing a European-wide supply issue relating to our equine influenza and influenza-tetanus vaccines.
"This has been caused by unexpected issues following the implementation of a technology upgrade and is not a product or quality issue.
"This means that some vet practices will have difficulty obtaining sufficient influenza vaccines and there may be a shortage in the UK market.
"We understand the importance of these vaccines to equine welfare, and we are continuing to work tirelessly to find a solution so that we can return to normal supply as soon as possible.”
Amanda Melvin, equine business manager at MSD Animal Health, said: “Based on prior demand, MSD’s equine vaccines Equilis Prequenza and Equilis Prequenza Te are in full supply.
"MSD have taken steps to protect as many horses as possible at this time.
"We will continue to supply existing customers with the available MSD stock on ‘allocation’ and, where possible, to allocate stock to additional customers. Allocations are being made to our veterinary customers based on their historical demand which we believe is the most efficient way to manage the available supplies.”
Rebecca Cabrejas, equine business unit manager at Zoetis, said: “Demand for our vaccines currently exceeds what we can supply.
"Whilst we have adequate stocks to fulfil current customers’ orders unfortunately, we are not in a position to be able to supply new customers at this time.
"We will continue to work with BEVA to limit the impact of the current shortages.”
Lanes Health, manufacturer of the mobility supplement, LitoVet, has announced the nominees for the inaugural Litovet Equine Scientific Achievement Award, part of the annual Animal Health Trust (AHT) awards.
The award which has been set up to recognise a person or group whose clinical or scientific work has made a substantial difference to the equine veterinary world will be judged by a panel of leading veterinary surgeons and scientists.
The nominees are:
Peter Clegg - MA VerMB PhD CertsES DepEVCS MRCVS. Dr Clegg is Professor of Equine Surgery and Deputy Head of the Institute of Ageing and Chronic Disease, Faculty of Health and Life Sciences, The University of Liverpool. Peter's current research focus is equine orthopaedics, in particular identifying the basic mechanisms of injury and repair in equine joints and tendons. He has supervised 13 successful PhD students and is currently supervising a further nine.
Andy Durham BSc, BVSc, DEIM, Dipl.ECEIM, MRCVS (RCVS & European Specialist in equine internal medicine). Liphook-based Andy Durham exemplifies the premise that veterinarians in practice can maintain an active interest in current research, undertake clinically relevant research projects, interact with researchers on an international stage and contribute to CPD through scientific papers, book chapters and lectures.
Tim Mair BVSc PhD DEIM DESTS DipECEIM MRCVS. Dr Mair ha been innovative in veterinary practice (e.g., an early adopter of standing magnetic resonance imaging [MRI]), has an extensive publication list recently focusing on evidence-based medicine for colic, but spanning the full breadth of common medical disorders in horses. He has made an enormous contribution to veterinary practice within both Europe and America in his role as Editor of Equine Veterinary Education.
Chris Proudman MA VetMB PhD CertEO FRCVS.Dr Proudman is Professor of Equine Studies at the University of Liverpool. His research interests are related to the aetiology and surgical management of acute intestinal disease (colic) in the horse: specifically, the diagnosis of intestinal parasites associated with colic and understanding dietary determinants of colic. Most recently this has involved using metabolomics and molecular microbiology to investigating the intestinal microbiota and its response to dietary change.
The LitoVet Equine Scientific Achievement Award can be granted to any individual or group that is currently undertaking, or has successfully implemented within the past ten years, one or more clinical or other research projects which has, or will, make a significant contribution to equine health and welfare.
The award will be presented to the recipient, or recipients, at the UK Equestrian Awards held at the Lancaster London on Thursday 3 November 2011.
Pfizer Animal Health is offering the chance to win £500 worth of CPD vouchers to UK veterinary surgeons who participate in the company's 5 minute online survey about Equine Herpes Virus (EHV).
Pfizer says the intention of the survey is to find out more about veterinary perceptions and understanding of this endemic disease and its effects on the UK's valuable equine industry. There are five multi-choice questions and the survey is available online from now until 31st May 2012. Vets who show their prowess in the skills-based section of the survey will be entered to win £500 of British Equine Veterinary Association CPD vouchers.
The survey is part of Pfizer's EHV awareness campaign to help vets encourage horse owners, yard managers, trainers and breeders to keep their horses protected from the effects of this common but often under-prioritised disease. The campaign includes the provision of information leaflets and the coordination of talks to help people, who manage horses, understand the severity of EHV and the best ways to prevent it.
According to Pfizer, the prevalence of EHV can be as high as 87.5% in the UK and latent infections in horses are frequently re-activated.1,2 The consequences can be serious, with abortion outbreaks proving to be a significant economic burden to owners, trainers and breeders.3,4 However, subclinical infections, although usually regarded as less serious, can remain unrecognised and can cause suboptimal performance in horses.
Sporadic, mild respiratory disease caused by EHV can lead to interrupted training and movement restrictions.4 Even after clinical recovery from EHV-1 or upper respiratory tract infections caused by EHV-4, some horse may develop 'poor performance syndrome'.5 These can all have serious financial repercussions on the equine industry.
To take part in the survey, visit http://www.ehvaware.com/. For further information on Pfizer's EHV campaign, to obtain literature for your practice or to book a talk for your clients please contact your Pfizer Account Manager.
1. Eddington et al. Equine Vet. J. 1994; 26 (2): 140-142. 2. Allen GP. 2002. Respiratory Infections by Equine Herpesvirus Types 1 and 4. In: P. Lekeux ed. 2002. Equine Respiratory Diseases. New York: International Veterinary Information Service. 3. Garré B et al. Vet Microbiol. 2007; 122(1-2): 43-51. 4. Lunn DP et al. J Vet Intern Med. 2009; 23(3): 450-61. 5. Slater, J. 2007. Equine Herpesvirus. In: Sellon, D. and Long, M. Equine Infectious Diseases. St Louis: Saunders. 144.
Dubbed the PICO Project, the scheme will initially run via a series of specialism-specific surveys that let respondents select individual species or topics and input the research questions they would like to see covered within Veterinary Evidence.
Knowledge will make the list of submitted questions available online for the veterinary community to answer as Knowledge Summaries (Critically Appraised Topics), which will be peer-reviewed and published in the open-access journal.
Professor Peter Cockroft, recently appointed Editor-in-chief of Veterinary Evidence, said: "The practice of evidence-based veterinary medicine is an empowering process for practicing veterinarians that enables important gaps in knowledge to be identified. It is the bridge between research and clinical practice.
"If you have a clinical question that may shape the care of a patient, Veterinary Evidence may have the best current answer or will add the question to the growing archive of important information needs."
The first survey to launch – open now – will focus on equine practice, with possible subjects ranging from the likes of husbandry or vaccination to infectious diseases.
To ask for the evidence on a particular area, choose your topic in the survey’s drop-down menus and fill in up to five related questions, preferably in Population Intervention Comparison Outcome format.
Livestock will be the focus for the next survey, due to open alongside the BCVA Congress in October. Further surveys will look at canines, felines and other specialisms.
To keep up to date with the list of PICO questions being answered or available to be answered, visit Veterinary Evidence and follow @RCVSKnowledge on Twitter.
If you wish to become an author of a Knowledge Summary for publication in the journal, contact the Managing Editor at Bridget@rcvsknowledge.org.